glp 1 receptor agonist 2

GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Tirzepatide sodium salt (LY3298176 sodium salt) is a GIP and GLP-1 receptor agonist with neuroprotective activity and can be used to treat obesity.

Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (EC50 value of 0.06 nM) used for the treatment of type 2 diabetes.

LY2922470 reduces glucose levels along with significant enhancements in insulin and GLP-1, which is the potential for the treatment of type 2 diabetes mellitus (T2DM). LY2922470 is an effective, selective, and orally available agonist of the G protein-cou

DA-JC4 is a compound with dual GLP-1 GIP receptor agonist properties. It is recommended for use in researching neurological diseases and investigating insulin signaling pathways[1][2][3].

Dapiglutide (ZP7570) is a long-acting dual agonist of both glucagon-like peptide-1 receptor (GLP-1R) and glucagon-like peptide-2 receptor (GLP-2R), with potential applications in short bowel syndrome (SBS) research.

Pal-Glu(OSu)-OH, a side chain specific to Liraglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes mellitus research.

Albiglutide TFA, a glucagon-like peptide (GLP)-1 mimetic, is a long acting GLP-1 receptor agonist. Albiglutide TFA significantly reduces glycosylated hemoglobin (A1C). Albiglutide TFA can be used for type 2 diabetes (T2D) research. Albiglutide TFA is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin [1] [2] [3] .

Dulaglutide (LY2189265), a glucagon-like peptide-1 (GLP-1) receptor agonist, is utilized in the study of type 2 diabetes (T2D) [1] [2].

Tirzepatide TFA (LY3298176 TFA), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is under development for type 2 diabetes treatment [1].

Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent GLP-2 receptor (GLP-2R) agonist, effectively reducing fecal output and enhancing intestinal absorption while alleviating small intestine inflammation. It holds potential for researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Glepaglutide (ZP1848) acetate is a long-acting glucagon-like peptide-2 (GLP-2) analogue and a potent GLP-2 receptor (GLP-2R) agonist. It significantly reduces fecal output and enhances intestinal absorption while also mitigating inflammation in the small intestine. Glepaglutide acetate is relevant in researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Pegapamodutide (LY-2944876), a dual glucagon-GLP-1 receptor agonist, is utilized in research concerning type 2 diabetes and obesity [1].

Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity.

Exendin-4 (3-39) is a truncated peptide variant of Exendin-4, missing the initial two amino acids, and serves as a potent agonist for the Glucagon-like peptide-1 receptor (GLP-1r). This compound, along with Exendin-4, is utilized in the study of diabetes and hypothalamic-pituitary-adrenal (HPA) axis disorders [1] [2].

Oxyntomodulin (swine), a peptide hormone secreted from the gastrointestinal tract after meals, serves as a dual agonist for the GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR). It plays a critical role in appetite suppression and the reduction of food intake [1] [2] [3].

Mazdutide (IBI-362; LY-3305677), a synthetic oxyntomodulin analog, serves as a glucagon-like peptide-1 (GLP-1R) glucagon receptor (GCGR) co-agonist. Demonstrating safety and tolerability, Mazdutide is utilized in obesity and type 2 diabetes (T2D) research [1] [2].

Albiglutide fragment (GLP-1 (7-36) analog) TFA represents a biologically active segment of Albiglutide, resistant to DPP-4 degradation due to its structure as a GLP-1 analog. It functions as a long-acting agonist of the GLP-1 receptor, derived from a fusion of a GLP-1 dimer with the human albumin gene. Clinically, this compound demonstrates a pronounced reduction in glycosylated hemoglobin (A1C) levels, rendering it a valuable therapeutic in type 2 diabetes (T2D) research [1] [2] [3] [4].

Mazdutide (IBI-362; LY-3305677) TFA is a dual agonist for the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), recognized as a long-acting synthetic oxyntomodulin analog. It demonstrates a favorable safety and tolerability profile and is utilized in research related to obesity and type 2 diabetes (T2D) [1] [2].

Pegloxenatide, a glucagon-like peptide-1 receptor (GLP-1 RA) agonist, is utilized in type 2 diabetes research [1].

Bamadutide (SAR425899) is a potent dual agonist for the glucagon-like peptide-1 receptor and glucagon receptor, enhancing β-cell function and reducing glucose absorption in vivo, thereby improving postprandial glucose control. This compound has potential applications in type 2 diabetes research [1].